{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"64.6","upperLimit":"93.8","value":"83.3"},{"groupId":"OG001","lowerLimit":"83.3","upperLimit":"100","value":"91.7"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"36"},{"groupId":"OG001","value":"11"}],"units":"Participants"}],"title":"EATING- Prior to treatment"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"60.4","upperLimit":"85.4","value":"75"},{"groupId":"OG001","lowerLimit":"75","upperLimit":"87.5","value":"83.3"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"24"},{"groupId":"OG001","value":"18"}],"units":"Participants"}],"title":"EATING- 6 months"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"66.7","upperLimit":"91.7","value":"83.3"},{"groupId":"OG001","lowerLimit":"62.5","upperLimit":"87.5","value":"83.3"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"23"},{"groupId":"OG001","value":"9"}],"units":"Participants"}],"title":"EATING- 12 months"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"67.7","upperLimit":"87.5","value":"77.1"},{"groupId":"OG001","lowerLimit":"75","upperLimit":"95.8","value":"95.8"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"16"},{"groupId":"OG001","value":"9"}],"units":"Participants"}],"title":"EATING- 24 months"}],"denoms":[{"counts":[{"groupId":"OG000","value":"36"},{"groupId":"OG001","value":"18"}],"units":"Participants"}],"description":"University of Michigan Head and Neck Quality of Life Instrument (HN-QOL) will be administered prior to treatment (i.e. pre-induction chemotherapy) and at 6 months, 12 months, and 24 months (+/- 4 months) after completion of chemo-RT or surgery-RT (or surgery-chemoRT, as indicated). Scale is 0-100 with high scores indicating a better outcome. EATING Domain is reported here as a functional assessment.","dispersionType":"Inter-Quartile Range","groups":[{"description":"platinum/docetaxel + AT-101 The platinum will either be cisplatin or carboplatin as deemed best by the medical oncologist.\n\nPatients underwent induction chemotherapy with (TP) docetaxel (Taxotere) 75 mg/m2 and cisplatin 100 mg/m2 (or Carboplatin AUC 6).\n\n(AT-101 Arm) Days #1-3: Patients received AT-101 40 mg orally twice daily On Day 23 (+/- 3 days), there will be a direct laryngoscopy (DL) with tumor biopsy and blood draw, repeat CT scan of the neck with perfusion within a week biopsy.\n\nAT-101: Patients received AT-101 40 mg orally two times a day.\n\nCisplatin: Cisplatin 100 mg/m2\n\nCarboplatin: Carboplatin AUC (area under the curve) 6. Maximum dose of 700 mg","id":"OG000","title":"Platinum/Docetaxal + AT-101"},{"description":"Patients underwent induction chemotherapy with (TP) docetaxel (Taxotere) 75 mg/m2 and cisplatin 100 mg/m2 (or Carboplatin AUC 6).\n\nDay #23 (+/- 3 days): Patients underwent a direct laryngoscopy (DL) with biopsy. Patients also underwent a repeat CT scan of the neck with perfusion within a week (+/-) of their perspective biopsies.\n\nDocetaxel: Docetaxel (Taxotere) 75 mg/m2\n\nCisplatin: Cisplatin 100 mg/m2\n\nCarboplatin: Carboplatin AUC (area under the curve) 6. Maximum dose of 700 mg","id":"OG001","title":"Active Comparator Arm"}],"paramType":"MEDIAN","populationDescription":"Number of participants analyzed varies below based on completion compliance","reportingStatus":"POSTED","timeFrame":"Up to 28 months post treatment","title":"Functional Assessment QOL","type":"SECONDARY","unitOfMeasure":"score on a scale"}